Rayno Biopharmaceuticals Portfolio in a Biotech Bull Market
Biotech Bull Market 2017 Performance as of 9/5/17 Rayno Biopharmaceutical Portfolio outperforms the market. XBI was the Best Play up 41.88% YTD. Biotech stocks broke through the July sector highs as tracked by major ETFs. However we are still about 25% off the July 2015 bubble highs but...
M&A Theme Continues To Boost Biotech Stocks
M&A Boosts Biotech Stocks For Third Day Gilead Sciences (GILD) and bluebird bio (BLUE) Both Soar Today Biotech Sector Back to 2017 Highs The prospect of more M&A boosts biotech stocks for a third day this week. The large cap based IBB was up 1.87% today and 6.48% over five days to...
At Last A Deal Sparks Biotech Rally: Gilead Buys Kite for $11.9B+…Update-1
Update-11:30am Aug 28 Green Screen in Biotech Especially CAR-T Plays (BLUE,CLLS,JUNO) NASDAQ up a tad 0.21%, but broad market flattish. Biotech Deal Boosts ETFs: FBT up 2.71%, IBB up 1.53%, XBI up 2.53%. Bellwether Celgene (CELG) up 1.4%. AMGN up 1.24%, BIIB up 2.67%, GILD up 1.57%. Mid-Caps:...
Vacation ’till August 26 Unless Unusual Vol
Not Much To Report-Vacation Doldrums Momentum Has Eased a Tad Investors Expecting Growth from Large Caps and M&A from Mid-Caps. We are on vacation until August 25 unless big news and volatility breaks. Here is where we are as of August 15: IBB at $309.31 off July peak YTD of $327, up 16.55%...
Biotech Snapshot on a Rally Day…Update-2
8/10 Red Screen in the Morning We cautioned on XBI at $78 on 7/31 and today it broke through support at $75 to $74.70. ======= 8/9 Update After Close: A Bit of Caution after Trump's "Fire and Fury" Talk Investors are holding off as global risks rise but biotech and healthcare holds July bottom...